Insulin premix formulation and product, methods of preparing same, and methods of using same
View Patent ↗A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.
1. A pharmaceutically acceptable insulin premix formulation comprising:
i) about 0.1 U to about 2.0 U of insulin/mL of the total formulation, and
ii) water,
wherein the insulin premix formulation has a pH value of about 6.5 to 7.2,
wherein the insulin premix formulation has no more than about 5.0% of A-21 desamido insulin impurity by weight of the total insulin based on percentage of peak area in relation to total insulin peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, when freshly prepared and after storage for 24 months at a refrigeration temperature of 2° C. to 8° C. followed by 30 days at a room temperature of 23° C. to 27° C. with substantially no exposure to light during the entire storage.
2. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation further comprises at least one tonicity adjuster.
3. The pharmaceutically acceptable insulin premix formulation according to claim 2 , wherein the tonicity adjuster is sodium chloride.
4. The pharmaceutically acceptable insulin premix formulation according to claim 3 , wherein the sodium chloride is about 0.80%-1.00% by weight of the formulation.
5. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation is sterile.
6. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation has no more than about 4.0% of A-21 desamido insulin impurity by weight of the total insulin based on percentage of peak area in relation to total insulin peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, when freshly prepared and after storage for 24 months at a refrigeration temperature of 2° C. to 8° C. followed by 30 days at a room temperature of 23° C. to 27° C. with substantially no exposure to light during the entire storage.
7. The pharmaceutically acceptable insulin premix formulation according to claim 1 , comprising about 0.5 U to about 2.0 U of the insulin/mL of the total formulation.
8. The pharmaceutically acceptable insulin premix formulation according to claim 1 , comprising about 1.0 U of the insulin/mL of the total formulation.
9. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation has a pH value of about 6.6 to 7.0.
10. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation has a pH value of 6.8±1%.
11. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation is essentially free of phenol, cresol, meta-cresol, parabens, any other added preservative, any added zinc, and any added glycerol.
12. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation has no more than about 3.0% of A-21 desamido insulin impurity by weight of the total insulin based on percentage of peak area in relation to total insulin peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, when freshly prepared and after storage for 24 months at a refrigeration temperature of 2° C. to 8° C. followed by 30 days at a room temperature of 23° C. to 27° C. with substantially no exposure to light during the entire storage.
13. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin premix formulation has no more than about 3.0% in total of insulin dimer, hexamer and other high molecular weight protein (HMWP) by weight of the total insulin, based on percentage of peak area in relation to total insulin peak area as measured by size exclusion chromatography (SEC), when freshly prepared and after storage for 24 months at a refrigeration temperature of 2° C. to 8° C. followed by 30 days at a room temperature of 23° C. to 27° C. with substantially no exposure to light during the entire storage.
14. The pharmaceutically acceptable insulin premix formulation according to claim 1 , wherein the insulin in monomer form is higher than 95% by weight of the total insulin.
15. A method of manufacturing a pharmaceutically acceptable insulin premix formulation, the method comprising:
adjusting the pH of a composition comprising water and about 0.1 U/mL to about 2.0 U/mL of insulin to a pH value of about 6.5 to 7.2,
wherein the insulin premix formulation has no more than about 5.0% of A-21 desamido insulin impurity by weight of the total insulin based on percentage of peak area in relation to total insulin peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, when freshly prepared and after storage for 24 months at a refrigeration temperature of 2° C. to 8° C. followed by 30 days at a room temperature of 23° C. to 27° C. with substantially no exposure to light during the entire storage.
16. The method according to claim 15 , further comprising adding at least one buffer to the composition before, during and/or after the adjusting of the pH and mixing the composition until homogeneous.
17. The method according to claim 15 , wherein the adjusting of the pH further comprises adding at least one tonicity adjuster to the composition and mixing the composition until homogeneous.
18. A pharmaceutically acceptable insulin premix product comprising a flexible container and further comprising a pharmaceutically acceptable insulin premix formulation in the flexible container, wherein the insulin premix formulation has been sterile-filled into the flexible container, and the insulin premix formulation comprises water and about 0.1 to about 10.0 U of insulin/mL of the total formulation, wherein the insulin premix formulation has a pH value of about 6.5 to 7.2.
19. The pharmaceutically acceptable insulin premix product according to claim 18 , wherein the flexible container has a volume of about 1.0-1000.0 ml.
20. The pharmaceutically acceptable insulin premix product according to claim 18 , wherein the flexible container has an inner surface layer contacting the insulin premix formulation, wherein the inner surface layer comprises at least one plastic material selected from the group consisting of a linear low density polyethylene (LLDPE), a polyvinyl chloride (PVC), a polypropylene (PP), a copolymer, and a modified polymer or copolymer.
21. A pharmaceutically acceptable insulin premix product comprising a flexible container and further comprising a pharmaceutically acceptable insulin premix formulation in the flexible container, wherein the insulin premix formulation has a pH value of about 6.5 to 7.2, wherein loss of insulin monomer in the insulin premix product is no more than about 8.0% by weight based on insulin monomer peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, after storage for at least one month at a refrigeration temperature of 2° C. to 8° C. with substantially no exposure to light during the entire storage.
22. The pharmaceutically acceptable insulin premix product according to claim 21 , wherein the insulin premix product has essentially no insulin adsorption or absorption to the flexible container throughout storage for at least one month at a refrigeration temperature of 2° C. to 8° C.
23. The pharmaceutically acceptable insulin premix product according to claim 21 , wherein the pharmaceutically acceptable insulin premix formulation has less than about 5.0% of A-21 desamido insulin impurity by weight of total insulin based on percentage of peak area in relation to total insulin peak area as measured by reverse-phase high performance liquid chromatography (HPLC) using UV at 214 nm wavelength for detection, throughout storage for at least one month at a refrigeration temperature of 2° C. to 8° C. with substantially no exposure to light during the entire storage.